Research Analysts’ Weekly Ratings Updates for Acadia Healthcare (ACHC)

Acadia Healthcare (NASDAQ: ACHC) recently received a number of ratings updates from brokerages and research firms:

• 5/4/2026 – Acadia Healthcare had its price target raised by Royal Bank Of Canada from $28.00 to $31.00. They now have an “outperform” rating on the stock.
• 5/4/2026 – Acadia Healthcare had its price target raised by Guggenheim from $26.00 to $31.00. They now have a “buy” rating on the stock.
• 5/4/2026 – Acadia Healthcare was upgraded by Raymond James Financial, Inc. from “outperform” to “strong-buy”. They now have a $39.00 price target on the stock.
• 5/1/2026 – Acadia Healthcare had its price target raised by Cantor Fitzgerald from $20.00 to $30.00. They now have a “neutral” rating on the stock.
• 4/30/2026 – Acadia Healthcare had its price target raised by Barclays PLC from $20.00 to $25.00. They now have an “equal weight” rating on the stock.
• 4/28/2026 – Acadia Healthcare had its price target raised by TD Cowen from $24.00 to $30.00. They now have a “buy” rating on the stock.
• 4/20/2026 – Acadia Healthcare had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $24.50 price target on the stock.
• 4/17/2026 – Acadia Healthcare had its price target raised by UBS Group AG from $27.00 to $31.00. They now have a “buy” rating on the stock.

Acadia Healthcare Company, Inc (NASDAQ: ACHC) is a publicly traded provider of behavioral healthcare services headquartered in Franklin, Tennessee. Founded in 2005, the company has grown through organic expansion and strategic acquisitions to establish itself as a leading specialist in mental health and addiction treatment across the United States.

Acadia operates a diversified network of inpatient psychiatric hospitals, residential treatment centers, outpatient clinics and intensive outpatient programs.